Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

NCT02716805 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped FDA placed on partial hold due to additional data

Conditions

Multiple Myeloma

Interventions

DRUG: Tremelimumab
DRUG: Durvalumab
BIOLOGICAL: Prevnar-13
DRUG: Melphalan

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]
[object Object]
[object Object]